We are live on ! Find out more
RNAM

Avidity Biosciences
RNAM

Delisted

RNAM was delisted on the 26th of February, 2026.

Back to rankings

0 hedge funds and large institutions have $0 invested in Avidity Biosciences in 2026 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% less ownership

Funds ownership: 0.01% → 0% (-0.01%)

100% less funds holding

Funds holding: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $236K → $0 (-$236K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
–
Holders Change
-1
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
CC
Corsicana & Co
Texas
-$236K

RNAM Hedge Fund Activity: Q2 2026 in Review

0 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q2 2026, worth a combined $0 — down 100% from $236K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of RNAM and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Corsicana & Co, exiting entirely with an estimated $236K sold.

  • 0 institutional investors held Avidity Biosciences (RNAM) as of Q2 2026, down from 1 in Q1 2026.
  • Funds reported $0 of Avidity Biosciences stock for Q2 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Avidity Biosciences positions in Q2 2026 and 1 closed out, a net change of -1 holder.
  • The largest Avidity Biosciences seller in Q2 2026 was Corsicana & Co, an estimated $236K sold.

Based on aggregated 13F filings for Q2 2026.